Back

GLP-2 predicts cardiovascular outcomes in patients with myocardial infarction and increases atherosclerosis in mice

27 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Bench to bedside in acute coronary syndromes: from infarction size in animal studies to long-term development of chronic coronary syndrome Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Florian Kahles

RWTH University Hospital Aachen, Aachen (Germany)

7 More presentations in this session

Presentation thumbnail
Circulating growth differentiation factor 11 exacerbates myocardial injury in mice and associates with increased infarct size in humans
Doctor A. Akhmedov (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Cardiomyocyte-specific beta3-adrenergic receptor expression reduces infarct size inhibiting the autophagic flux in mice.
Mr M. Fernandez Tocino (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Malonate protection against acute infarction in isolated mouse hearts is lost in the presence of insulin
Miss Q. Wang (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
A long-term prognostic factor for cardiovascular risk in patients with chest pain without diabetes mellitus and significant coronary stenosis
Miss J. Cha (KR)
Abstract Slides Video
Presentation thumbnail
Health outcomes in patients with chronic coronary syndromes due to obstructive or non-obstructive coronary arteries.
Ms S. La (Adelaide, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Bench to bedside in acute coronary syndromes: from infarction size in animal studies to long-term development of chronic coronary syndrome

The Event

Event poster

ESC Congress 2023

27 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Session
Molecular actions of GLP-1 agonists and incretins
thumbnail
Congress Presentation
State-of-the-art lecture on molecular actions of GLP-1 agonists and incretins
thumbnail
Congress Presentation
Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources